Get access

Seroprevalence of hepatitis C in patients with type 2 diabetes mellitus and non-diabetic on haemodialysis

Authors

  • S. Ocak,

    Corresponding author
    1. Department of Infectious Diseases and Clinical Microbiology,1 Department of Microbiology and Clinical Microbiology,2 Department of Internal Medicine,3 Medical Faculty, Mustafa Kemal University, Antakya Emir Haemodialysis Center,4 Department of Internal Medicine, Hatay, Turkey
    Search for more papers by this author
  • 1 N. Duran,

    1. Department of Infectious Diseases and Clinical Microbiology,1 Department of Microbiology and Clinical Microbiology,2 Department of Internal Medicine,3 Medical Faculty, Mustafa Kemal University, Antakya Emir Haemodialysis Center,4 Department of Internal Medicine, Hatay, Turkey
    Search for more papers by this author
  • 2 H. Kaya,

    1. Department of Infectious Diseases and Clinical Microbiology,1 Department of Microbiology and Clinical Microbiology,2 Department of Internal Medicine,3 Medical Faculty, Mustafa Kemal University, Antakya Emir Haemodialysis Center,4 Department of Internal Medicine, Hatay, Turkey
    Search for more papers by this author
  • and 3 İ. Emi̇r 4

    1. Department of Infectious Diseases and Clinical Microbiology,1 Department of Microbiology and Clinical Microbiology,2 Department of Internal Medicine,3 Medical Faculty, Mustafa Kemal University, Antakya Emir Haemodialysis Center,4 Department of Internal Medicine, Hatay, Turkey
    Search for more papers by this author

*Dr Sabahattin Ocak, Assistant Professor, Department of Infectious Diseases and Clinical Microbiology, Medical Faculty, Mustafa Kemal University, Hatay, Turkey
Tel.: + 90 326 214 3699
Fax.: + 90 326 214 4976
Email: sabahattinocak@hotmail.com

Summary

Type 2 diabetes mellitus (DM) has emerged as the commonest cause of end-stage renal disease. Haemodialysis (HD) treatment constitutes a high-risk environment for the transmission of hepatitis C virus (HCV). The aim of this study was to establish a potential relationship between type 2 DM and HCV infection in HD patients. Of the 267 HD patients, 67 (25.1%) had type 2 DM and 200 (74.9%) were with diverse aetiology for end-stage renal disease. The serum markers of HCV infection were tested by a second-generation enzyme-linked immunosorbent assay test for antibodies and by qualitative reverse-transcription polymerase chain reaction technique for viral RNA. The overall prevalence of anti-HCV antibodies and HCV RNA was found to be 12.7% (34/267) and 10.1% (27/267), respectively. Patients with type 2 DM were found to have a higher HCV prevalence compared with non-diabetic patients [20.8% (14/67) vs. 10% (20/200)] (p < 0.05). The mean period on dialysis of anti-HCV-positive patients with type 2 DM was shorter than that observed for anti-HCV-positive non-diabetic patients (43.9 ± 9.8 months vs. 59.7 ± 28.4 months) (p < 0.05). This study has shown that although the period on dialysis of diabetic patients are shorter than non-diabetic patients, the prevalence of HCV in HD patients with type 2 DM is higher than that detected in non-diabetic HD patients.

Ancillary